Dizal Pharmaceutical 迪哲医药
5 significant filings since 31 May 2026: 2 on major holder selling, 2 on guarantee or financial assistance and 1 on earnings pre-announcement. The latest, on 25 Sep 2026: 迪哲医药：关于高级管理人员减持股份计划公告. On 24 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 44.35% from the same period a year earlier.
自 31 May 2026 起有 5 份重大公告：major holder selling 2 份、guarantee or financial assistance 2 份、earnings pre-announcement 1 份。最新一份（25 Sep 2026）：迪哲医药：关于高级管理人员减持股份计划公告。24 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 44.35%。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 东海证券 | 杜永宏 | Buy 买入 | 7 Sep 2026 | 3 | — |
| 中邮证券 | 盛丽华,陈灿 | Buy 买入 | 25 Aug 2026 | 1 | — |
| 东吴证券 | 朱国广,肖鸿德 | Buy 买入 | 22 Aug 2026 | 2 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 6 reports. 每行为该券商近十二个月的最新研报；6 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。